Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026!This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges.🎧 Lis...

In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the comp...

From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech.In this episode of Petri Dish Perspectives: Biote...

In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the...

Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world.In this epi...

Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026!This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball.🎧 Li...

Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything.In this episod...

In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotec...

In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused busin...

What if medicine could fix disease at its source… by rewriting the genetic code itself?In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transform...

Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026!This month was dominated by a surge in Eli Lilly's deals, partnerships, etc. 🎧 Listen now, stay curious, and don’t forg...

What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away?In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its ...

Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his ...

Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial ...

Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history. In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its f...

Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness.

Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025!This month was dominated by a surge in M&A activity and licensing deals.🎧 Listen now, stay curious, and don’t forget to...

Before there were blockbuster drugs, clinical trials, and biotech startups, there was… dye.In this episode of Petri Dish Perspectives, we explore one of the most overlooked origin stories in modern medicine: how 19th-century che...

In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Progra...

In this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making orig...

Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation.In this deep-div...

Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025!This month was dominated by a surge in M&A activity, with high-profile bidding wars! 🎧 Listen now, stay curious, a...

Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targe...

In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two ph...

In this episode of Petri Dish Perspectives, we dive into the untold story of Charles River Laboratories, the quiet giant behind nearly every major drug you’ve ever heard of.From its origins on the banks of Massachusetts’ ...